

20th November | Afternoon

13:00 | 14:00

WELCOME

14:00 | 15:00

OPENING CEREMONY

15:00 | 16:30

ANTI-BACTERIAL ANTIBODIES

Chair: Philippe Thullier / Nathalie Heuzé-Vourc'h

- **Development of a recombinant IgG neutralizing the anthrax lethal toxin**
Thibaut Pelat, Institut de Recherche Biomédicale des Armées, France
- **Development of heavy chain antibodies against the Penton-Valentine leukocidine from *S. aureus***
Dubravka Drabek, Erasmus Medical Center, Netherlands
- **Human monoclonal antibodies against Staphylococcal enterotoxin B: inhibitors of toxic shock**
Bradley G. Stiles, Wilson College, USA

16:30 | 17:00

COFFEE BREAK

17:00 | 18:30

ANTI-VIRAL ANTIBODIES

Chair: Isabelle Dimier-Poisson / Denys Brand

- **Human mAbs against Hendra and Nipah viruses: from discovery in academic setting to administration in humans**
Dimiter S. Dimitrov, Frederick National Laboratory for Cancer Research, NIH, USA
- **Rewriting history: antibody therapeutics for filoviruses**
John M. Dye, USAMRIID, USA
- **Isolation and characterization of scFvs targeting filoviruses**
Jeffrey W. Froude, USAMRMC, USA

21st November | Morning

08:00 | 08:30

WELCOME

08:30 | 09:30

ANTI-MICROBIAL ANTIBODIES

AND EFFECTOR FUNCTIONS

Chair: Dominique Buzoni-Gatel / Gilles Thibault

- **Development of panobacumab, anti-*P. aeruginosa* LPS serotype IATS O11**
Antonio Perez, Kenta Biotech, Switzerland
- **IgG-FcγR binding and effector functions**
Pierre Bruhns, Institut Pasteur, France
- **An endogenous human antibody directed against a conserved epitope of M2 confers full protection against various Influenza A strains in an *in vivo* model system**
Anton Bauer, Intercell, Austria

09:30 | 10:00

COFFEE BREAK

10:00 | 11:00

KEYNOTE LECTURE

Chair: Mustapha Si-Tahar

- **Broadly neutralising antibodies for therapy and vaccine design**
Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland

11:00 | 12:30

ANTI-VIRAL ANTIBODIES

Chair: Francis Barin / Stéphane Paul

- **Broadly neutralizing antibodies present new prospects to counter HIV infection**
Pascal Poignard, The Scripps Research Institut, USA
- **Nanobodies based on a dromadary single-domain antibody targeting HIV-1 reverse transcriptase**
Naima Abidi-Azzouz, Centre de Recherches de Biochimie Macromoléculaire, France

12:30 | 14:00

LUNCH

21st November | Afternoon

14:00 | 15:30

ANTI-VIRAL ANTIBODIES

Chair: Philippe Roingard / Valérie Gouilleux-Gruart

- **From polyclonal immunoglobulin to monoclonal antibody: an urgent need for rabies post-exposure prophylaxis**
Laurent Dacheux, Institut Pasteur, France
- **Broadly neutralizing alpaca nanobody blocks virus entry and cell-cell transmission of hepatitis C virus**
Pierre Lafaye, Institut Pasteur, France
- **Targeting host entry factors for prevention and treatment of hepatitis C virus infection**
Mirjam Zeisel, University of Strasbourg, France

15:30 | 16:30

KEYNOTE LECTURE

Chair: Hervé Watier

- **Regulatory aspects in the development of monoclonal antibody cocktails**
Patrick G. Swann, Office of Biotechnology Products, FDA, USA

16:30 | 17:00

COFFEE BREAK

17:00 | 18:30

INVOLVEMENT OF THE FRENCH BIOTECH INDUSTRY IN THE FIELD

Chair: Jean-Luc Teillaud / André Pèlerin

- **Development of anti-Shiga toxin mAbs**
Christian Behrens, LFB Biotechnologies, France
- **The ISAAC and VIVA SCREEN platforms for the generation of human mAbs**
Majid Mehtali, Vivalis, France
- **Monoclonal antibodies against infectious diseases at SANOFI: where are we?**
Laurent Fraise, SANOFI, France

20:00 |

GALA DINNER